Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Growth Hormone Deficiency
Interventions
DRUG

Recombinant Human Growth Hormone

300 mcg sc qd (which may be increased to 400 mcg sc qd after 4 weeks)

DRUG

Recombinant Human IGF-1

30 µg/kg for first 4 weeks (may be increased thereafter based on IGF-1 levels)

Trial Locations (1)

10032

Columbia University, College of Physicians and Surgeons, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Tercica

INDUSTRY

lead

Columbia University

OTHER